STAB2

STAB2 (Stabilin-2/HARE) is a type I transmembrane scavenger receptor on sinusoidal endothelial cells of liver, spleen, and lymph nodes that mediates clathrin-dependent endocytic clearance of hyaluronan, chondroitin sulfates, heparin, advanced glycation end products, and other polyanionic ligands, and activates ERK1/2 signaling upon ligand internalization (PMID:10952975, PMID:12473645, PMID:33126404). The receptor recycles with an ~8.5-minute turnover and delivers cargo to lysosomes for degradation, with endocytosis driven by three redundant cytoplasmic motifs (YSYFRI, FQHF, NPLY) that together account for ~95% of coated-pit-mediated uptake (PMID:12933790, PMID:18539600). The full-length Stab2 isoform additionally mediates phagocytosis of apoptotic cells and bacteria, whereas a proteolytically derived 190-kDa HARE isoform handles clearance of all known soluble ligands including unfractionated and low-molecular-weight heparin (PMID:19359419, PMID:33126404). Rare damaging STAB2 variants with reduced surface expression are associated with venous thromboembolism, consistent with impaired clearance of procoagulant factors (PMID:32457982).

1. 2000 High

   Identification of HARE as the endocytic hyaluronan receptor on liver sinusoidal endothelial cells resolved the long-standing question of which receptor mediates systemic HA clearance, revealing both 175-kDa and 300-kDa species recognized by blocking monoclonal antibodies.

   Evidence Monoclonal antibody development with 125I-HA binding/endocytosis inhibition on rat liver SECs and tissue immunofluorescence

   PMID:10952975

   Open questions at the time

   • Molecular identity and cDNA of HARE not yet cloned
   • Relationship between 175-kDa and 300-kDa species unclear
2. 2002 High

   Demonstration that STAB2 (FEEL-2) binds and endocytoses AGE-modified proteins with scavenger receptor-like pharmacology expanded its ligand repertoire beyond glycosaminoglycans to include damaged proteins.

   Evidence 125I-AGE-BSA binding, uptake, and degradation assays in CHO cells overexpressing FEEL-2 with polyanionic competitor controls

   PMID:12473645

   Open questions at the time

   • Structural basis for AGE recognition unknown
   • Physiological relevance of AGE clearance by STAB2 in vivo not tested
3. 2003 High

   Antibody-blocking experiments in ex vivo perfused rat livers established HARE/Stabilin-2 as the physiological receptor for systemic HA clearance, moving beyond cell-line evidence to organ-level function; parallel reconstitution of the 175-kDa isoform revealed its GAG specificity, recycling kinetics, and lysosomal delivery pathway.

   Evidence Anti-HARE mAb blocking in perfused liver and primary SECs; recombinant 175-kDa receptor in SK-Hep-1 cells with 125I-HA endocytosis, recycling, and ligand competition assays

   PMID:12645574 PMID:12933790

   Open questions at the time

   • Whether the 300-kDa full-length form has identical GAG specificity not determined
   • In vivo knockout model not yet available
4. 2004 High

   Reconstitution of the human 190-kDa HARE isoform confirmed rapid, continuous HA endocytosis with ~8.5-min recycling and established quantitative binding parameters (Kd ~7 nM), validating cross-species conservation of receptor function.

   Evidence Stable Flp-In 293 cells expressing human 190-kDa HARE, 125I-HA endocytosis with kinetic and competition analyses

   PMID:15208308

   Open questions at the time

   • Full-length human Stab2 not yet functionally reconstituted
   • Structural basis of HA–Link domain interaction unresolved
5. 2008 High

   Systematic mutagenesis of the cytoplasmic tail identified three redundant endocytic motifs (YSYFRI, FQHF, NPLY) that together mediate ~95% of coated-pit-dependent HA internalization, establishing the molecular mechanism of receptor sorting.

   Evidence Site-directed and deletion mutagenesis of cytoplasmic motifs in stable cell lines, quantitative 125I-HA endocytosis assay

   PMID:18539600

   Open questions at the time

   • Direct interaction with AP-2 subunits not biochemically demonstrated
   • Whether motif usage differs for non-HA ligands unknown
6. 2009 High

   Identification of HARE/Stabilin-2 as the clearance receptor for both unfractionated and low-molecular-weight heparin explained the differential pharmacokinetics of clinical heparins through affinity differences (Kd ~0.06 vs. ~10 µM).

   Evidence Anti-HARE antibody blocking in primary SECs, recombinant receptor and purified soluble ecto-domain binding assays

   PMID:19359419

   Open questions at the time

   • Whether STAB2-mediated heparin clearance is rate-limiting in vivo not confirmed by knockout
   • Binding site for heparin vs. HA not structurally resolved
7. 2010 High

   Mutagenesis of N-glycosylation at the Link domain (N2280) dissociated HA binding to the soluble ecto-domain from cellular endocytosis, revealing that N-glycans are required for ligand capture by the ecto-domain but not for membrane-bound receptor function.

   Evidence N2280A mutagenesis with ELISA, pull-down, surface plasmon resonance, and endocytosis assays

   PMID:20466649

   Open questions at the time

   • How membrane context compensates for loss of N-glycan-dependent binding is mechanistically unexplained
   • No crystal structure of Link domain available
8. 2018 Medium

   Zebrafish loss-of-function demonstrated that Stab2 is essential for anionic nanoparticle uptake by sinusoidal endothelial cells in vivo, extending the receptor's scavenger function to synthetic nanomaterials.

   Evidence Zebrafish stab2 morpholino knockdown, nanoparticle biodistribution imaging, dextran sulfate competitive inhibition

   PMID:29320626

   Open questions at the time

   • Morpholino knockdown may have off-target effects; genetic null not confirmed in this study
   • Relevance to mammalian nanoparticle pharmacokinetics not directly shown
9. 2020 Medium

   Rare damaging STAB2 variants linked to venous thromboembolism showed reduced cell-surface expression, connecting receptor haploinsufficiency to impaired clearance of procoagulant factors and human disease.

   Evidence Whole-exome sequencing gene-burden analysis in VTE cohorts; cell-surface expression assay of VTE-associated STAB2 variants

   PMID:32457982

   Open questions at the time

   • Direct demonstration that STAB2 clears VWF or FVIII not shown in this study
   • Animal model rescue not performed
   • Variant effects on ligand binding and endocytosis not measured
10. 2020 Medium

    Functional dissection established that full-length Stab2 mediates phagocytosis of apoptotic cells and bacteria while the HARE isoform handles all known soluble ligands, and that ligand-induced endocytosis activates ERK1/2 signaling, adding a signaling dimension to the receptor's clearance role.

    Evidence Endocytosis and phagocytosis assays, ERK1/2 signaling readouts, domain dissection of full-length vs. HARE isoform

    PMID:33126404

    Open questions at the time

    • Downstream targets of ERK1/2 activation in SECs not identified
    • Physiological consequence of STAB2-mediated ERK signaling unknown

• Key unresolved questions include the structural basis of STAB2's broad ligand recognition, how the full-length isoform enables phagocytosis that the HARE isoform cannot, the physiological significance of STAB2-activated ERK1/2 signaling, and the direct causal mechanism linking STAB2 deficiency to venous thromboembolism.
• No crystal or cryo-EM structure of STAB2 ecto-domain
• Mammalian Stab2 knockout phenotype not comprehensively described in the timeline
• Direct clearance of coagulation factors by STAB2 not biochemically demonstrated